A combination of molecular biology and conventional drug screening promises to expedite the identification of compounds against fungal diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
De Backer, M. D. et al. Nat. Biotechnol. 19, 235–241 (2001).
Beck-Sague, C.M. & Jarwis, W.R. J. Infect. Dis. 167, 1247–1251 (1993).
Chiou, C.C., Groll, A.H. & Walsh, T.J. Oncologist 5, 120–135 (2000).
Georgopapadakou, N.H. Curr. Opin. Microbiol 1, 547–557 (1998).
Sanglard, D. et al. Antimicrob. Agents Chemother. 39, 2378–2386 (1995).
Clarke, M.L., Patrikakis, M. & Atkins, D. Biochem. Biophys. Res. Commun. 268, 8–13 (2000).
Giaever, G. et al. Nat. Genet. 21, 278–283 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sanglard, D. Integrated antifungal drug discovery in Candida albicans. Nat Biotechnol 19, 212–213 (2001). https://doi.org/10.1038/85634
Issue Date:
DOI: https://doi.org/10.1038/85634